UK study shows ctDNA blood test can predict how advanced breast cancer patients will respond to therapy: Doctor explains what it is

Breast cancer remains a major global health burden—about 2.3 million women were diagnosed in 2022 with roughly 670,000 deaths—and it is now the most common cancer among women in India, with many cases detected at advanced stages. Researchers at The Institute of Cancer Research, London, reported in Clinical Cancer Research that circulating tumour DNA (ctDNA) measured in blood correlates with response to targeted therapies (low baseline and four‑week levels associated with treatment response). Dr. Arun Kumar Goel highlights that ctDNA monitoring can reduce some invasive biopsies and help track resistance but cannot replace initial diagnostic tissue biopsies due to issues like low shedding and sanctuary sites. The findings principally matter for diagnostics, precision‑medicine and biotech companies developing liquid‑biopsy technologies rather than posing an immediate macro market driver.

Analysis

Market structure: Liquid‑biopsy ctDNA adoption favors molecular diagnostics and sequencing-rights holders (Guardant Health GH, Illumina ILMN, Myriad MYGN, Thermo Fisher TMO, Roche RHHBY) and oncology drugmakers selling targeted therapies; pathology/imaging providers that rely on repeat invasive biopsies face revenue displacement. Expect pricing pressure on single-test margins but strong volume growth for labs that capture recurring monitoring (potential addressable market expansion of tens of percent over 2–5 years if payer coverage arrives).

Risk assessment: Tail risks include regulatory/reimbursement rejection (CMS/NICE denial) and sensitivity limitations (false negatives) that could stifle uptake — both are low probability but high impact within 6–18 months. Near‑term shocks: negative large prospective trial or supply disruptions (sequencer reagents) could compress valuations; medium/long term risk is commoditization driving reagent price cuts 20–40% over 2–4 years.

Trade implications: Favor diagnostics/consumables exposure and underweight legacy pathology/imaging. Use concentrated, conditional exposure: buy GH/ILMN for commercial and reagent leverage, hedge with shorts in imaging/pathology providers (RDNT, DG, LH). Options: use 9–15 month call spreads to cap premium while retaining upside to binary clinical/reimbursement catalysts.

Contrarian angles: Consensus overestimates near‑term replacement of biopsies — ctDNA will likely be additive first (monitoring/resistance detection) and only later broadly diagnostic; many small cap specialist plays are already priced for perfection. Historical parallel: 2016–19 liquid biopsy hype saw 30–70% reversals after negative readouts; position sizing and catalyst gating are essential to avoid binary drawdowns.

Key Decisions for Investors

• Establish a 2–3% long position in Guardant Health (GH) and 1–2% in Illumina (ILMN) with a 12–24 month horizon to capture commercial ctDNA volume growth; trim/stop-loss if shares fall >30% or if CMS/payer coverage is explicitly denied within 12 months.
• Buy a limited‑risk 9–15 month call spread on GH (buy 1 near‑the‑money call, sell 1 120% strike) sized 0.5–1% of portfolio to capture upside from positive large trial or major payer coverage; target 40–100% spread return on success.
• Initiate a pair trade: long 1–2% Apollo Hospitals (APLLTD.NS) / short 1% RadNet (RDNT). Rationale: integrated hospital networks gain treatment volume from earlier detection; standalone imaging chains risk replacement/reduced repeat scans. Rebalance after 6–12 months or upon policy shifts.
• Reduce exposure by 3–5% to legacy pathology/diagnostic reporting names (Quest DG, LabCorp LH) until two of the following occur: (a) definitive CMS/NICE positive coverage, (b) a prospective >500‑patient study with sensitivity/specificity >90%, or (c) a major pharma‑diagnostic commercial partnership — expected timeline 6–18 months.
• Monitor three binary catalysts over the next 6–12 months and act decisively: (1) CMS/payer reimbursement decision, (2) publication of a large prospective validation (>500 patients) showing clinical utility, (3) payer/pricing agreements or top‑tier pharma partnerships. Increase allocations if at least two catalysts clear in favor.